Suppression of postoperative liver metastases from colon cancer by continuous intraportal infusion of an angiogenesis inhibitor FR-118487

I. Eda, H. Soga, M. Ueoka, K. Yamashita, S. Kawasaki, H. Doihara, R. Hirai, N. Shimizu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A rabbit VX2 colon cancer model with spontaneous liver metastases was used to evaluate the antitumor effect of an angiogenesis inhibitor, FR-118487. FR- 118487 (1 mg/kg/day) was infused continuously into the portal vein for a week after resection of primary colon cancer lesions (FR group). The incidence of liver metastases was 71.4% (5/7) in FR group, and 100% (7/7) in control group. The numher and the weight of liver metastatic nodules were 31.0±36.0 and 1.4±1.8 g in FR group versus 83.7±73.9 and 6.5±4.9 g in control group, respectively. The metastases in FR group were significantly decreased in weight compared with those in control group (p<0.05). No anastomotic leakage was recognized in either group. No side effects of FR-118487 such as body weight loss were found. Continuous intraportal infusion of FR-118487 in the early postoperative period may be effective to suppress liver metastases from colon cancer by inhibiting the angiogenesis concerning liver metastases.

Original languageEnglish
Pages (from-to)1480-1482
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume22
Issue number11
Publication statusPublished - 1995

Keywords

  • Colon cancer
  • Continuous intraportal infusion
  • FR-118487
  • Liver metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Suppression of postoperative liver metastases from colon cancer by continuous intraportal infusion of an angiogenesis inhibitor FR-118487'. Together they form a unique fingerprint.

  • Cite this